LifeTech Capital Maintains Strong Buy on Oculus Innovative Sciences

LifeTech Capital is out with its report today on Oculus Innovative Sciences OCLS, maintaining Strong Buy. In a note to clients, LifeTech Capital writes, "We believe shares of Oculus Innovative Sciences are undervalued and are maintaining Oculus with a Strong Buy rating and a 12-18 month Price Target of $4.75. Our valuation is based on a 35x multiple on projected fiscal year 2014 EPS and discounted 15% for cumulative risk." Shares of OCLS closed Friday at $1.72.